JUVAF (Juva Life) EBITDA Margin %: -22.26% (As of Mar. 2023)


What is Juva Life EBITDA Margin %?

Juva Life JUVAF -90.00% EBITDA Margin % is -22.26% as of Mar. 2023.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Juva Life's EBITDA for the three months ended in Mar. 2023 was $-0.38 Mil. Juva Life's Revenue for the three months ended in Mar. 2023 was $1.73 Mil. Therefore, Juva Life's EBITDA margin for the quarter that ended in Mar. 2023 was -22.26%.

Juva Life  (OTCPK:JUVAF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Juva Life EBITDA Margin % Related Terms

Juva Life EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Juva Life's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Juva Life EBITDA Margin % Chart

Juva Life Annual Data
Trend Dec19 Dec20
EBITDA Margin %
0.00 -1,553.26

Juva Life Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Mar22 Jun22 Sep22 Mar23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -83.81 -219.97 -69.71 -130.93 -22.26

JUVAF vs AVRW, UPC, EVOK: EBITDA Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Juva Life's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Juva Life EBITDA Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Juva Life's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Juva Life's EBITDA Margin % falls into.


Juva Life EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Juva Life's EBITDA Margin % for the fiscal year that ended in Dec. 2020 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2020 )/Revenue (A: Dec. 2020 )
=-15.02/0.967
=-1,553.26 %

Juva Life's EBITDA Margin % for the quarter that ended in Mar. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2023 )/Revenue (Q: Mar. 2023 )
=-0.384/1.725
=-22.26 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -22.26% mean?
Juva Life (JUVAF) has a EBITDA Margin % of -22.26% as of Mar. 2023. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Juva Life and its competitors.
Is Juva Life's EBITDA Margin % too high?
Juva Life's current EBITDA Margin % is -22.26%.
How does Juva Life's EBITDA Margin % compare to AVRW and UPC?
Juva Life's EBITDA Margin % of -22.26% can be compared against companies in the Drug Manufacturers industry. The industry median EBITDA Margin % is 12.52. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Juva Life and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Juva Life's current EBITDA Margin % is -22.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Juva Life stock overvalued right now?
Juva Life (JUVAF) has a current EBITDA Margin % of -22.26%. The current EBITDA Margin % is -22.26%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Juva Life (JUVAF), the current EBITDA Margin % is -22.26% as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Juva Life Business Description

Address 885 West Georgia Street, Suite 1400, Vancouver, BC, CAN, V6C 3E8
Juva Life Inc is a life science company with both pharmaceutical research and development and consumer facing operations in cannabis production and distribution.